Want to see DE:EVT full AI Analyst Report?
Top Page
Evotec
(XETRA:EVT)
Select Model
Select Model
Rating:41Neutral
Price Target:
€2.50
▼(-23.08% Downside)
Action:Reiterated
Date:08/18/26
The score is primarily held down by weak financial performance, led by ongoing losses, margin compression, and negative operating/free cash flow. Technical signals also remain bearish with price below key moving averages and a negative MACD. Valuation is additionally constrained by a negative P/E (loss-making) and no provided dividend yield to offset the risk profile.
Positive Factors
Integrated drug-discovery platform
An integrated platform spanning multiple stages of drug development can deepen partner relationships and increase the range of work Evotec can capture per program. This broad capability supports strategic relevance to pharmaceutical and biotechnology customers over multiple development cycles.
Negative Factors
Persistent losses and margin pressure
Sustained losses and sharply reduced margins indicate that current operations are not yet generating attractive economic returns. The weak profitability limits internal funding capacity and makes improvement in pricing, mix, costs or utilization important for durable earnings recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated drug-discovery platform
An integrated platform spanning multiple stages of drug development can deepen partner relationships and increase the range of work Evotec can capture per program. This broad capability supports strategic relevance to pharmaceutical and biotechnology customers over multiple development cycles.
Read all positive factors
Evotec (EVT) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€437.04M
Dividend YieldN/A
Average Volume (3M)1.07M
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue Growth-7.72%
EPS Growth-26.61%
CountryDE
Employees4,461
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.11
Shares Outstanding177,909,970
10 Day Avg. Volume1,287,934
30 Day Avg. Volume1,074,964
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.19
Price to Sales (P/S)1.23
P/FCF Ratio-11.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.80Price Target Upside109.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.29
Revenue Forecast (FY)€600.71M
Evotec Business Overview & Revenue Model
Company Description
Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a d...
How the Company Makes Money
Evotec makes money primarily through (1) fee-for-service and (2) partnered R&D economics that can include milestones and royalties (or other downstream participation), depending on the collaboration structure.
1) Fee-for-service / contract resear...
Evotec Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 717.28M | 788.37M | 796.97M | 781.43M | 751.45M | 618.03M |
| Gross Profit | 75.25M | 65.24M | 114.88M | 175.05M | 174.06M | 151.54M |
| EBITDA | -27.86M | -41.40M | -80.66M | 877.00K | -86.08M | 298.41M |
| Net Income | -197.05M | -103.52M | -196.08M | -83.91M | -175.66M | 215.51M |
Balance Sheet | ||||||
| Total Assets | 1.57B | 1.78B | 1.91B | 2.25B | 2.26B | 2.24B |
| Cash, Cash Equivalents and Short-Term Investments | 465.59M | 476.39M | 396.80M | 604.11M | 729.98M | 858.50M |
| Total Debt | 475.87M | 447.69M | 463.10M | 626.20M | 506.67M | 512.92M |
| Total Liabilities | 908.40M | 965.05M | 959.98M | 1.13B | 1.07B | 857.48M |
| Stockholders Equity | 665.58M | 813.70M | 952.52M | 1.12B | 1.19B | 1.38B |
Cash Flow | ||||||
| Free Cash Flow | -162.03M | -81.98M | -114.02M | -179.56M | 21.75M | 3.29M |
| Operating Cash Flow | -113.84M | -9.44M | 18.22M | 36.44M | 203.11M | 122.24M |
| Investing Cash Flow | 217.23M | 166.42M | -71.19M | -13.29M | -415.82M | -243.85M |
| Financing Cash Flow | -20.79M | -32.20M | -161.42M | 71.96M | -52.41M | 398.43M |
Evotec Technical Analysis
Negative
3.25
Price Trends
3.12
Negative
3.79
Negative
4.59
Negative
Market Momentum
-0.14
Positive
26.35
Positive
1.92
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EVT, the sentiment is Negative. The current price of 3.25 is above the 20-day moving average (MA) of 2.84, above the 50-day MA of 3.12, and below the 200-day MA of 4.59, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 26.35 is Positive, neither overbought nor oversold. The STOCH value of 1.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:EVT.
Evotec Risk Analysis
Evotec disclosed 10 risk factors in its most recent earnings report. Evotec reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Evotec Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | €60.28B | 25.25 | 8.08% | 1.60% | -0.40% | -17.22% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €17.62M | -1.49 | -127.78% | ― | ― | ― | |
45 Neutral | €58.11M | -4.09 | 590.52% | ― | ― | ― | |
43 Neutral | €106.20M | -3.21 | 444.89% | ― | 77.97% | -41.49% | |
41 Neutral | €437.04M | -2.21 | -26.46% | ― | -7.72% | -26.61% |
* General Sector Average
DE:EVT
Evotec
2.44
-4.28
-63.67%
DE:B8FK
Biofrontera
2.93
0.24
8.92%
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
2.70
0.59
27.96%
DE:MRK
Merck KGaA
137.60
23.44
20.53%
DE:HPHA
Heidelberg Pharma AG
2.25
-0.76
-25.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.